1.Application of bicuspid pulmonary valve sewn by 0.1 mm expanded polytetrafluoroethylene in right ventricle outflow tract reconstruction
Jianrui MA ; Tong TAN ; Miao TIAN ; Jiazichao TU ; Wen XIE ; Hailong QIU ; Shuai ZHANG ; Jian ZHUANG ; Jimei CHEN ; Jianzheng CEN ; Shusheng WEN ; Haiyun YUAN ; Xiaobing LIU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(08):1127-1132
		                        		
		                        			
		                        			Objective  To introduce a modified technique of right ventricular outflow tract (RVOT) reconstruction using a handmade bicuspid pulmonary valve crafted from expanded polytetrafluoroethylene (ePTFE) and to summarize the early single-center experience. Methods  Patients with complex congenital heart diseases (CHD) who underwent RVOT reconstruction with a handmade ePTFE bicuspid pulmonary valve due to pulmonary regurgitation at Guangdong Provincial People’s Hospital from April 2021 to February 2022 were selected. Postoperative artificial valve function and right heart function indicators were evaluated. Results  A total of 17 patients were included, comprising 10 males and 7 females, with a mean age of (18.18±12.14) years and a mean body weight of (40.94±19.45) kg. Sixteen patients underwent reconstruction with a handmade valved conduit, with conduit sizes ranging from 18 to 24 mm. No patients required mechanical circulatory support, and no in-hospital deaths occurred. During a mean follow-up period of 12.89 months, only one patient developed valve dysfunction, and no related complications or adverse events were observed. The degree of pulmonary regurgitation was significantly improved post-RVOT reconstruction and during follow-up compared to preoperative levels (P<0.001). Postoperative right atrial diameter, right ventricular diameter, and tricuspid regurgitation area were all significantly reduced compared to preoperative values (P<0.05). Conclusion  The use of a 0.1 mm ePTFE handmade bicuspid pulmonary valve for RVOT reconstruction in complex CHD is a feasible, effective, and safe technique.
		                        		
		                        		
		                        		
		                        	
2.A case of surgical resection for gallbladder carcinoma with multiple liver metastases after downgrading transformation with the combination of immunotherapy and radiation therapy.
Yong Qiang YANG ; Zhi Gang CHEN ; Wen Lu ZHAO ; Jian TU ; Ye TIAN ; Shao Hua WEI ; Wei CHEN
Chinese Journal of Oncology 2023;45(5):452-454
3.A Novel Early Warning Model for Hand, Foot and Mouth Disease Prediction Based on a Graph Convolutional Network.
Tian Jiao JI ; Qiang CHENG ; Yong ZHANG ; Han Ri ZENG ; Jian Xing WANG ; Guan Yu YANG ; Wen Bo XU ; Hong Tu LIU
Biomedical and Environmental Sciences 2022;35(6):494-503
		                        		
		                        			Objectives:
		                        			Hand, foot and mouth disease (HFMD) is a widespread infectious disease that causes a significant disease burden on society. To achieve early intervention and to prevent outbreaks of disease, we propose a novel warning model that can accurately predict the incidence of HFMD.
		                        		
		                        			Methods:
		                        			We propose a spatial-temporal graph convolutional network (STGCN) that combines spatial factors for surrounding cities with historical incidence over a certain time period to predict the future occurrence of HFMD in Guangdong and Shandong between 2011 and 2019. The 2011-2018 data served as the training and verification set, while data from 2019 served as the prediction set. Six important parameters were selected and verified in this model and the deviation was displayed by the root mean square error and the mean absolute error.
		                        		
		                        			Results:
		                        			As the first application using a STGCN for disease forecasting, we succeeded in accurately predicting the incidence of HFMD over a 12-week period at the prefecture level, especially for cities of significant concern.
		                        		
		                        			Conclusions
		                        			This model provides a novel approach for infectious disease prediction and may help health administrative departments implement effective control measures up to 3 months in advance, which may significantly reduce the morbidity associated with HFMD in the future.
		                        		
		                        		
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Cities/epidemiology*
		                        			;
		                        		
		                        			Data Visualization
		                        			;
		                        		
		                        			Disease Outbreaks/statistics & numerical data*
		                        			;
		                        		
		                        			Forecasting/methods*
		                        			;
		                        		
		                        			Hand, Foot and Mouth Disease/prevention & control*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Neural Networks, Computer
		                        			;
		                        		
		                        			Reproducibility of Results
		                        			;
		                        		
		                        			Spatio-Temporal Analysis
		                        			;
		                        		
		                        			Time Factors
		                        			
		                        		
		                        	
4.Factors associated with positive results in English literature of acupuncture for chronic pain.
Ying LIN ; Ji-Ping ZHAO ; Shi-Yan YAN ; Jian-Feng TU ; Li-Qiong WANG ; Jin-Ling LI ; Na ZHANG ; Yu WANG ; Xuan ZOU ; He-Wen LI ; Cun-Zhi LIU
Chinese Acupuncture & Moxibustion 2022;42(5):573-578
		                        		
		                        			OBJECTIVE:
		                        			To analyze the main factors affecting the positive results of acupuncture for chronic pain in English literature of randomized controlled trial (RCT), in order to provide reference for the design of acupuncture clinical research.
		                        		
		                        			METHODS:
		                        			The RCTs of acupuncture for chronic pain published before March 26, 2020 were searched in PubMed, EMbase and Cochrane Library by computer. A total of 21 factors were analyzed by single-factor analysis, and the factors with statistically significant difference were selected for multivariate Logistic regression analysis.
		                        		
		                        			RESULTS:
		                        			A total of 69 RCTs were included, including 47 RCTs (68.12%) with positive results and 22 RCTs (31.88%) with non-positive results. The multivariate Logistic regression analysis was performed with the three screened factors (publication year, treatment frequency and intervention form) selected by single-factor analysis, and the results showed that the positive results were related to the frequency of acupuncture treatment. The positive rate of RCT with frequency≥2 times a week was 3.24 times of that with frequency<2 times a week (OR=3.24, 95%CI =[1.07,9.83], P<0.05).
		                        		
		                        			CONCLUSION
		                        			Acupuncture frequency may be the main factor affecting the positive results of RCT in English literature of acupuncture for chronic pain. More researches are needed in the future to explore the influence of acupuncture frequency on the curative effect.
		                        		
		                        		
		                        		
		                        			Acupuncture
		                        			;
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Chronic Pain/therapy*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			PubMed
		                        			
		                        		
		                        	
5.Association of Residential Greenness with the Prevalence of Metabolic Syndrome in a Rural Chinese Population: the Henan Rural Cohort Study.
Ya Ling HE ; Xiao Tian LIU ; Run Qi TU ; Ming Ming PAN ; Miao Miao NIU ; Gong Bo CHEN ; Jian HOU ; Zhen Xing MAO ; Wen Qian HUO ; Shan Shan LI ; Yu Ming GUO ; Chong Jian WANG
Biomedical and Environmental Sciences 2022;35(1):89-94
6.The Mechanism of Artesunate Combined with Cytarabine and/or Daunorubicin on the Apoptosis of MV4-11 MLL-rearranged Acute Myeloid Leukemia Cell Line.
Jian-Yun LI ; Xin XIONG ; Dian-Wen WANG ; Xu-Yan ZHANG ; Can HUANG ; Ling-Li ZOU ; Cai-Feng ZHENG ; Xin CHEN ; Chuan-Qing TU
Journal of Experimental Hematology 2022;30(6):1724-1729
		                        		
		                        			OBJECTIVE:
		                        			To investigate the effect and mechanism of artesunate (ARTS) combined with cytarabine(Ara-C) and/or daunorubicin (DNR) on the proliferation and apoptosis of MV4-11 human mixed-lineage leukemia rearranged(MLL-r) acute myeloid leukemia (AML) cell line.
		                        		
		                        			METHODS:
		                        			CCK-8 assay was used to detect the proliferation effect of individual or in combination of ARTS, DNR, Ara-C on MV4-11 cells. The IC50 of ARTS, DNR and Ara-C was calculated separately. The cell apoptosis and expression of receptors DR4 and DR5 were detected by flow cytometry. Western blot was used to detect the expression of Caspase-3 and Caspase-9 in each groups.
		                        		
		                        			RESULTS:
		                        			The inhibition effect of ARTS, Ara-C and DNR on the proliferation of MV4-11 were all dose-dependently (r=0.99, 0.90 and 0.97, respectively). The IC50 of ARTS, Ara-C and DNR on MV4-11 for 48 hours were 0.31 μg/ml, 1.43 μmol/L and 22.47 nmol/L, respectively. At the dose of ARTS 0.3 μg/ml, Ara-C 1.0 μmol/L and DNR 15 nmol/L, the proliferation rate for 48 hours of the tri-combination treatment was significantly lower than that of the bi-combination treatment, while both were significantly lower than that of the individual treatment (all P<0.05). In terms of bi-combination treatment, the cells proliferation rate for 48 hours of the ARTS+Ara-C group was significantly lower than that of the ARTS+DNR group, while both were significantly lower than that of the Ara-C+DNR group (all P<0.05). The cooperativity index (CI) of bi- and tri-combination treatment were all less than 1. After 48 hours of drug action, the cell apoptosis rate of the ARTS+DNR+Ara-C group was significantly higher than that of the Ara-C+DNR group, while both were significantly higher than that of the ARTS+DNR group (all P<0.05). Meanwhile, the was no statistical difference between the cells apoptotic rate of the ARTS+DNR+Ara-C group and the ARTS+Ara-C group (P>0.05). The expression of DR4 and DR5 also showed no difference between control group and drug group. Compared with the DNR+Ara-C group, the expressions of Caspase-3 were significantly down-regulated in both the ARTS+DNR+Ara-C group and the ARTS+Ara-C group (all P<0.05). The down-regulation of Caspase-3 expression was the most significantly in the combination group of three drugs, while the Caspase-9 expressions in different groups showed no apparent change.
		                        		
		                        			CONCLUSION
		                        			The in vitro study showed that tri-combination of ARTS+Ara-C+DNR and bi-combination of ARTS+Ara-C could inhibit the proliferation and promote apoptosis of MV4-11 cell line. The inhibition effect of these two combinations were significantly superior to that of the traditional Ara-C+DNR treatment. The mechanism underlying this finding may be identified by the down regulation of Caspase-3, while no altered expression was observed of Caspase-9, DR4 and DR5.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Cytarabine/pharmacology*
		                        			;
		                        		
		                        			Daunorubicin/pharmacology*
		                        			;
		                        		
		                        			Caspase 3
		                        			;
		                        		
		                        			Caspase 9
		                        			;
		                        		
		                        			Artesunate/pharmacology*
		                        			;
		                        		
		                        			Leukemia, Myeloid, Acute
		                        			;
		                        		
		                        			Apoptosis
		                        			;
		                        		
		                        			Cell Line
		                        			
		                        		
		                        	
7.Effect of acupuncture on knee injury and osteoarthritis outcome score in patients with knee osteoarthritis.
Jian-Feng TU ; Li-Qiong WANG ; Guang-Xia SHI ; Jing-Wen YANG ; Jin-Ling LI ; Yong-Ting LI ; Jing-Jie ZHAO ; Hai-Kun HOU ; Yi DU ; Cun-Zhi LIU
Chinese Acupuncture & Moxibustion 2021;41(1):27-30
		                        		
		                        			OBJECTIVE:
		                        			To verify the clinical effect of acupuncture on knee osteoarthritis (KOA).
		                        		
		                        			METHODS:
		                        			Forty-two patients with KOA were randomly divided into an acupuncture group (21 cases, 1 case dropped off) and a sham acupuncture group (21 cases, 1 case dropped off). The patients in the acupuncture group were treated with routine acupuncture at 5-6 local acupoints [Dubi (ST 35), Neixiyan (EX-LE 4), Heding (EX-LE 2), Yinlingquan (SP 9), Xuehai (SP 10), Zusanli (ST 36), etc.] and 3-4 distal acupoints [Fengshi (GB 31), Waiqiu (GB 36), Xuanzhong (GB 39), Zulinqi (GB 41), etc.]. The patients in the sham acupuncture group were treated with shallow needling technique at non-acupoint. The needles were retained for 30 min in both groups. All the treatment was given three times a week for 8 weeks. Knee injury and osteoarthritis outcome score (KOOS) were recorded before and after treatment and 18-week follow-up.
		                        		
		                        			RESULTS:
		                        			Compared before treatment, the scores of 5 dimensions of KOOS [pain, symptoms (except pain), daily activities, sports and entertainment, and quality of life] were increased after treatment and during follow-up in the two groups (
		                        		
		                        			CONCLUSION
		                        			Acupuncture can reduce the pain symptoms and improve daily activities in patients with KOA.
		                        		
		                        		
		                        		
		                        			Acupuncture Points
		                        			;
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Knee Injuries
		                        			;
		                        		
		                        			Osteoarthritis, Knee/therapy*
		                        			;
		                        		
		                        			Quality of Life
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
8.Application and reflection on pilot study in acupuncture clinical research.
Yu WANG ; Li-Qiong WANG ; Jing-Wen YANG ; Guang-Xia SHI ; Jian-Feng TU ; Shi-Yan YAN ; Cun-Zhi LIU
Chinese Acupuncture & Moxibustion 2021;41(3):325-329
		                        		
		                        			
		                        			Pilot study is essential prerequisite for large-scale research. Acupuncture is a complex intervention measure. The factors of its clinical effect and effect mechanism are complicated. Hence, the resource waste is easily induced in research if the large-scale clinical research is rashly carried out before scientific verification. Currently, there is still a lack of high-quality evidence of clinical research, which affects the promotion and application of the curative effect of acupuncture. The pilot study of acupuncture can evaluate the feasibility and the process coordination of trial, optimize program and process and provide the basis of sample size calculation prior to launching a full-scale trial. Thereby, the methodological quality of acupuncture research and the reliability of trial results can be improved. In the paper, the arguments focus on the definition, design and report of pilot study so as to provide the approaches and references for the design and implementation of pilot study of clinical research of acupuncture.
		                        		
		                        		
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Pilot Projects
		                        			;
		                        		
		                        			Reproducibility of Results
		                        			;
		                        		
		                        			Research Design
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
9.Molecular regulative mechanisms of NLRP3 inflammasome activation in diabetic nephropathy and interventional effects of Chinese herbal medicine.
Wen-Wen WANG ; Wen-Bei HAN ; Yi-Gang WAN ; Yue TU ; Bu-Hui LIU ; Ying-Lu LIU ; Wei WU ; Hong-Yun YEE ; Qi-Jun FANG ; Jian YAO
China Journal of Chinese Materia Medica 2020;45(1):7-13
		                        		
		                        			
		                        			The progression of renal damage in diabetic nephropathy(DN)is closely related to Nod-like receptor protein3(NLRP3)inflammasome activation. The characteristics of NLRP3 inflammasome activation include the changed expression and combination levels of NLRP3, apoptosis-associated speck-like protein(ASC)and pro-caspase-1, the increased expression levels of caspase-1, interleukin(IL)-1β and IL-18 and the excessive release levels of the relative inflammatory mediators. Its molecular regulative mechanisms involve the activation of multiple signaling pathways including reactive oxygen species(ROS)/thioredoxin-interacting protein(TXNIP)pathway, nuclear factor(NF)-κB pathway, nuclear factor erythroid-related factor 2(Nrf2)pathway, long non-coding RNA(lncRNA)pathway and mitogen-activated protein kinases(MAPKs)pathway. In addition, more importantly, never in mitosis aspergillus-related kinase 7(Nek7), as a kinase regulator, could target-combine with NLRP3 at upstream to activate NLRP3 inflammasome. Some extracts of Chinese herbal medicines(CHMs)such as quercetin, curcumin, cepharanthine, piperine and salidroside, as well as Chinese herbal compound prescriptions such as Wumei Pills both could treat NLRP3 inflammasome to ameliorate inflammatory renal damage in DN. Therefore, accurately clarifying the targets of anti-inflammatory CHMs and Chinese herbal compound prescriptions delaying DN progression by targeting the molecular regulative mechanisms of NLRP3 inflammasome activation will be one of the development directions in the future.
		                        		
		                        		
		                        		
		                        			Caspase 1/immunology*
		                        			;
		                        		
		                        			Diabetes Mellitus/drug therapy*
		                        			;
		                        		
		                        			Diabetic Nephropathies/immunology*
		                        			;
		                        		
		                        			Drugs, Chinese Herbal/therapeutic use*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammasomes/immunology*
		                        			;
		                        		
		                        			Interleukin-18/immunology*
		                        			;
		                        		
		                        			Interleukin-1beta/immunology*
		                        			;
		                        		
		                        			NIMA-Related Kinases
		                        			;
		                        		
		                        			NLR Family, Pyrin Domain-Containing 3 Protein/immunology*
		                        			
		                        		
		                        	
10.A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
Lin CAI ; Gen-Hui CHEN ; Qian-Jin LU ; Min ZHENG ; Yu-Zhen LI ; Jin CHEN ; Jie ZHENG ; Fu-Ren ZHANG ; Jian-Bin YU ; Sen YANG ; Fu-Qiu LI ; Sheng-Xiang XIAO ; Qiu-Ning SUN ; Jin-Hua XU ; Xing-Hua GAO ; Hong FANG ; Tian-Wen GAO ; Fei HAO ; Quan-Zhong LIU ; Ya-Ting TU ; Ruo-Yu LI ; Bao-Xi WANG ; Dan-Qi DENG ; Qing-Shan ZHENG ; Hong-Xia LIU ; Jian-Zhong ZHANG
Chinese Medical Journal 2020;133(24):2905-2909
		                        		
		                        			BACKGROUND:
		                        			Benvitimod cream, a novel synthetic small molecule, was effective in treating mild-to-moderate plaque psoriasis. We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.
		                        		
		                        			METHODS:
		                        			We randomly assigned 686 patients (2:1:1) to receive 1% benvitimod cream, 0.005% calcipotriol ointment or placebo twice a day for 12 weeks. The primary efficacy end points were the percentage of patients with a 75% or greater reduction from baseline in the psoriasis area and severity index (PASI 75) score and with a score of 0 or 1 in static physician's global assessment (sPGA) at week 12.
		                        		
		                        			RESULTS:
		                        			The results showed that 50.4% of patients in the benvitimod group achieved PASI 75, which was significantly higher than that in the calcipotriol (38.5%, P < 0.05) and placebo (13.9%, P < 0.05) groups. The proportion of patients achieving an sPGA score 0 or 1 was 66.3% in the benvitimod group and 63.9% in the calcipotriol group, which were both significantly higher than that in the placebo group (34%, P < 0.05). In the long-term follow-up study, 50.8% of patients experienced recurrence. After retreatment with 1% benvitimod, 73.3% of patients achieved an sPGA score of 0 or 1 again at week 52. Adverse events included application site irritation, follicular papules, and contact dermatitis. No systemic adverse reactions were reported.
		                        		
		                        			CONCLUSION:
		                        			During this 12-week study, benvitimod cream was demonstrated with high effectiveness and safety in patients with mild-to-moderate plaque psoriasis.
		                        		
		                        			TRIAL REGISTRATION
		                        			Chinese Clinical Trial Registry (ChiCTR), ChiCTR-TRC-13003259; http://www.chictr.org.cn/showprojen.aspx?proj=6300.
		                        		
		                        		
		                        		
		                        			Double-Blind Method
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Ointments
		                        			;
		                        		
		                        			Psoriasis/drug therapy*
		                        			;
		                        		
		                        			Resorcinols
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			;
		                        		
		                        			Stilbenes
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail